Literature DB >> 20627205

Sources of variation in factor VIII, von Willebrand factor and fibrinogen measurements: implications for detecting deficiencies and increased plasma levels.

Juergen Bach1, Hanne Haubelt, Peter Hellstern.   

Abstract

OBJECTIVES: Differences in pre-analytical and assay conditions, inappropriate reference ranges, or inflammation may have the potential to impair clinical decisions based on measurements of factor VIII (FVIII), von Willebrand factor (VWF) and fibrinogen (Fg). This study examined the impact on FVIII, VWF and Fg in plasma of freezing and thawing, different citrate anticoagulant concentrations, and inflammation, as determined by high-sensitivity C-reactive protein (hsCRP).
MATERIALS AND METHODS: FVIII was determined prior to freezing and after thawing using a one-stage clotting assay (FVIII:C), an amidolytic assay (FVIII:AM) and an enzyme immunoassay (FVIII:Ag). Samples were anticoagulated with 106 or 129 mmol/L of citrate. FVIII, VWF and Fg were quantified in 300 individuals to establish reference ranges and to investigate associations with hsCRP.
RESULTS: Freezing and thawing reduced FVIII:C and FVIII:AM markedly. FVIII coagulant activities were not significantly different between samples anticoagulated with 106 or 129 mmol/L of citrate, respectively. FVIII, VWF and Fg were significantly associated with hsCRP. FVIII:C was greater than FVIII:AM and FVIII:Ag in all experiments, indicating that the presence of activated FVIII may lead to overestimation of FVIII:C.
CONCLUSIONS: Standardized freezing and thawing of plasma samples appears to be indispensable if reliable FVIII results are to be obtained. Because inflammation can potentially mask deficiency states or mimic an increased risk of thrombosis, FVIII, VWF and Fg determinations should be supplemented by measurements of hsCRP. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20627205     DOI: 10.1016/j.thromres.2010.05.029

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia.

Authors:  Margaret V Ragni; Rachel C Jankowitz; Kristen Jaworski; Elizabeth P Merricks; Mark T Kloos; Timothy C Nichols
Journal:  Thromb Haemost       Date:  2011-08-11       Impact factor: 5.249

Review 2.  Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories.

Authors:  A Magnette; M Chatelain; B Chatelain; H Ten Cate; F Mullier
Journal:  Thromb J       Date:  2016-12-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.